Marker X offers an AI-driven, non-invasive blood test for early cancer detection using proteomic analysis. The service identifies subtle protein expression changes to detect cancers at their earliest stages, providing a more accurate and accessible screening solution.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers are detected at late stages, significantly reducing treatment efficacy and survival rates. Traditional screening methods often lack sensitivity for early-stage disease or are invasive, leading to patient reluctance and missed opportunities for timely intervention.
Solution
Marker X provides an AI-driven, multi-cancer early detection screening service utilizing proteomics analysis of blood samples. This non-invasive approach identifies cancer at its earliest stages by analyzing subtle protein expression changes in the blood. The platform leverages a proprietary multi-marker algorithm and AI to achieve high sensitivity and specificity, offering a more accurate and accessible screening solution. Beyond early detection, Marker X also offers proteomic analysis services to support scientific research and development, aiding in the discovery of new biomarkers and therapeutic targets.
Target Audience
The primary target audience includes individuals aged 35 and above, particularly those with risk factors such as family history, unhealthy lifestyle habits, or high stress levels, as well as healthcare providers and research institutions seeking advanced proteomic analysis capabilities.
Features
- Non-invasive blood-based proteomic analysis for early cancer detection.
- AI-powered multi-marker algorithm for enhanced diagnostic accuracy and reduced false positives/negatives.
- Capable of detecting early-stage cancers, including Stage 0 and Stage I.
- Analyzes a panel of protein biomarkers to provide a comprehensive risk assessment.
- Offers proteomic analysis services for research and development, including custom assay development.
- Utilizes high-resolution mass spectrometry for precise protein quantification.
- Provides personalized health recommendations and customized clinical guidance based on test results.
- Supports the development of companion diagnostics for targeted therapies.